Physician profile
Sarav Daid
NPI 1881117299
$1,066.59
in general payments reported to CMS, 2019-2025
15 companies · $350 in 2025
The $350 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $110 · 2023: $27.47 · 2024: $175 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $272.64 | 2019-2025 | Epclusa |
| Abbvie INC. | $176.50 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $161.96 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.73 | 2024-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.06 | 2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $54.64 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $52.75 | 2019 | |
| Mallinckrodt Hospital Products INC. | $38.50 | 2024-2025 | Terlivaz |
| Micro-Tech Endoscopy USA, INC. | $35.28 | 2025 | |
| Janssen Biotech, INC. | $25.56 | 2025 | Tremfya |
| Phathom Pharmaceuticals, INC. | $22.91 | 2024 | Voquezna |
| Viiv Healthcare Company | $21.43 | 2020 | |
| Intercept Pharmaceuticals, INC. | $19.65 | 2025 | |
| Madrigal Pharmaceuticals | $16.25 | 2024 | Resmetirom |
| Novartis Pharmaceuticals Corporation | $11.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarav Daid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.